Fremanezumab Managed Access Program for Pediatric Patients

Available (expanded access)

Conditions studied: Migraine

In brief

This is a Managed Access Program (MAP) based on a licensed physician's unsolicited request on a compassionate basis. Specifically, this MAP is for male and female pediatric patients 6 to 17 years with a diagnosis of either episodic or chronic migraine who have successfully completed the Teva sponsored study TV48125-CNS-30084 (SPACE study).

Key facts

Study ID

NCT03539393

Run by

Teva Branded Pharmaceutical Products R&D LLC

Last updated by the study team

2026-07-27

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eligible patients may enter this CUP after successfully completing TV48125-CNS-30084 and all End of Study procedures
• In the opinion of your physician/investigator are able to continue IMP (fremanezumab) in a safe and compliant way.

You may not qualify if…

• Additional criteria may apply, please contact your physician/investigator for more information.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.